Skip to main content

Table 1 Patient and tumor characteristics stratified by ER Status of recurrent tumor

From: TROP2 methylation and expression in tamoxifen-resistant breast cancer

  ERpos primary to ERneg (n = 6) ERpos primary to ERpos (n = 12)   
Patients   
 Age (in years) mean (SD), range   
  At primary 53 (8.1), 42–65 58 (15.8), 37–84   
  At recurrence 60 (6.1), 53–68 65 (15.6), 40–90   
 Menopausal n (%)   
  At primary 2 (33%) 6 (50%)   
  At recurrence 3 (50%) 8 (66.6%)   
TTR (in months) mean (SD), range 82.8 (77.6) 17–216 84.1 (72.5), 12–252   
  ERpos primary (n = 6) ERneg recurrent (n = 6) ERpos primary (n = 12) ERpos recurrent (n = 12)
Tumors
 PR status n (%)
  + 3 (50) 0 11 (91.6) 9 (75)
  − 3 (50) 6 (100) 1 (8.3) 3 (25)
 HER2 status n (%)
  + 2 (33.3) 3 (50) 1 (8.3) 2 (16.6)
  − 4 (66.6) 3 (50) 11 (91.6) 10 (83.4)
 Ki67 IHC n (%)
  Low (≤ 15) 6 (100) 4 (66.6) 9 (75) 8 (66.6)
  High (> 15) 0 2 (33.3) 3 (25) 4 (33.4)
 Tumor grade n (%)a
  0 2 (33.3) 2 (33.3) 1 (9.1) 2 (16.7)
  1 0 0 3 (27.3) 2 (16.7)
  2 3 (50) 0 4 (36.3) 3 (25)
  3 1 (16.6) 4 (66.6) 3 (27.3) 5 (41.6)
 Tumor type n (%)
  DCIS 2 (33.3) 2 (33.3) 1 (8.3) 2 (16.7)
  IDC 3 (50) 4 (66.6) 8 (66.7) 6 (50)
  ILC 0 0 2 (16.7) 3 (25)
  IDLC 1 (16.6) 0 1 (8.3) 1 (8.3)
  1. See text for scoring of ER, PR, HER2 and Ki67
  2. TTR time to recurrence
  3. aIndicates that data are missing for some samples; percentages are calculated on the available data